Yahoo Finance

LifeStance Health Group (NASDAQ:LFST) First Quarter 2025 Results

Key Financial Results

• Revenue: US$333.0m (up 11% from 1Q 2024).

• Net income: US$709.0k (up from US$21.1m loss in 1Q 2024).

• Profit margin: 0.2% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.

• EPS: US$0.002 (up from US$0.056 loss in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

LifeStance Health Group Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 16% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for LifeStance Health Group that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.